Moderna Will Start To Outrun Coronavirus Competition In 2021, Analyst Says

Oppenheimer analyst Hartaj Singh maintained an Outperform rating and a $108 price target.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.